Abstract
The article contains results of two studies assessing efficacy and safety of rivaroxaban in routine clinical practice which were presented at European Congress of Cardiology 2015. These studies (recently completed XANTUS and ongoing post-marketing safety surveillance study in the United States) in total included more than 45 000 patients from Europe, Russia, Canada and the United States.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
